Announcement on January 28

Hanmi Pharmaceutical announced on January 28 that it has signed an export supply agreement with Mexican pharmaceutical company Laboratorios Sanfer for its diabetes treatments, Dapharon Tablets and Dapharon Duo Extended-Release Tablets.

Product images of Dapharon Tablets and Dapharon Duo Extended-Release Tablets. Hanmi Pharmaceutical

Product images of Dapharon Tablets and Dapharon Duo Extended-Release Tablets. Hanmi Pharmaceutical

View original image

The contract amount is 65,861,193,333 KRW, which is equivalent to 4.40% of the company’s most recent sales of 1,495,515,755,068 KRW. The amount in Korean won was calculated based on the Seoul Money Brokerage Services exchange rate of 1,467.20 KRW per US dollar as of January 26, 2026.


The contract period is 10 years, from January 26, 2026 to January 26, 2036. The sales and supply territory is Mexico. Detailed payment terms, including any advance payments, have not been disclosed. The contract amount includes both milestone payments and the projected sales over the 10-year period as agreed by both companies.



Following the signing of the agreement, Hanmi Pharmaceutical plans to conduct due diligence on local regulatory approvals and intellectual property (IP) rights. If the due diligence results determine that commercialization in Mexico is impossible due to IP issues, or if regulatory risks are deemed high, a portion of the contract amount may be refunded and the contract may be terminated. The contract may also be terminated if local regulatory approval is not obtained.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing